|
typ |
publikacja |
300 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
301 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
336 |
Czasopismo |
Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409. |
404 |
Czasopismo |
Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299. |
616 |
Czasopismo |
Jump WG, Plaza VM, Poremba A. Compatibility of nalbuphine hydrochloride with other preoperative medications. Am J Hosp Pharm 1982 ; 39: 841-843. |
642 |
Czasopismo |
Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59. |
660 |
Czasopismo |
Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232. |
921 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
1057 |
Czasopismo |
Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
1203 |
Czasopismo |
Yuhas EM, Lofton FT, Baldinus JG, Mayron D. Cimetidine hydrochloride compatibility with preoperative medications. Am J Hosp Pharm 1981 ; 38: 1173-1174. |
1415 |
Czasopismo |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74. |
1625 |
Czasopismo |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
1628 |
Czasopismo |
Das Gupta V. Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes. Int J Pharm Compound 2001 ; 5: 482-484. |
1803 |
Czasopismo |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
1925 |
Czasopismo |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
3379 |
Czasopismo |
Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524. |
3501 |
Laboratorium |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics Pfizer 2011 |
3503 |
Laboratorium |
Fentanyl - Summary of product Characteristics Hameln Pharmaceuticals 2012 |
3525 |
Laboratorium |
Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012 |
3526 |
Laboratorium |
Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010 |
3531 |
Laboratorium |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014 |
3592 |
Laboratorium |
Cimetidine - Résumé des caractéristiques du produit Sandoz 2008 |
3596 |
Laboratorium |
Chlorpromazine (Largactil®) - Summary of Product Characteristics Sanofi 2014 |
3599 |
Laboratorium |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013 |
3631 |
Laboratorium |
Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit Aguettant 2016 |
3674 |
Laboratorium |
Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016 |
3676 |
Laboratorium |
Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit Hospira 2014 |
3931 |
Laboratorium |
Trimébutine (Débridat®) - Résumé des caractéristiques du produit Pfizer Laboratoire 2016 |
3932 |
Laboratorium |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015 |
4009 |
Laboratorium |
Droperidol - Résumé des Caractéristiques du Produit Panpharma 2017 |
4303 |
Czasopismo |
Anderson C, MacKay M. Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes. Pharmacy 2015 3, 379-385. |
4428 |
Czasopismo |
Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132. |
4700 |
Laboratorium |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics AS Kalceks 2022 |